Spondyloarthritis (SpA) is a group of diseases with similar clinical, radiologic and serologic features, including SpA associated with inflammatory bowel disease (IBD-associated SpA). Several studies have estimated the occurrence of SpA in IBD patients as ranging from 17% to 39%, confirming that SpA is the most frequent extra-intestinal manifestation in patients with IBD. In this paper, the expert panel presents some red flags to guide clinicians both rheumatologists and gastroenterologists - to make a correct diagnosis of IBD-associated SpA in clinical practice. IBD-associated SpA classification, clinical presentation and diagnostic work-up are also presented. From the therapeutic point of view, only separate recommendations/guidelines are currently available for the treatment of Crohn's disease, ulcerative colitis and for both axial and peripheral SpA. However, when IBD and SpA coexist, the therapeutic strategy should be modulated to take into account the variable manifestations of IBD in terms of intestinal and extra-intestinal features, and the clinical manifestations of SpA, with particular attention to peripheral enthesitis, dactylitis and anterior uveitis. To our knowledge, this is the first attempt to define therapeutic algorithms for the integrated management of different IBD-associated SpA clinical scenarios.

Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease / I. Olivieri, F.C. Fcastiglione, C. Felice , P. Gionchetti, A. Orlando, C. Salvarani, R. Scarpa, M. Vecchi, A. Armuzzi. - In: AUTOIMMUNITY REVIEWS. - ISSN 1568-9972. - 13:8(2014), pp. 822-830. [10.1016/j.autrev.2014.04.003]

Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease

M. Vecchi
Penultimo
;
2014

Abstract

Spondyloarthritis (SpA) is a group of diseases with similar clinical, radiologic and serologic features, including SpA associated with inflammatory bowel disease (IBD-associated SpA). Several studies have estimated the occurrence of SpA in IBD patients as ranging from 17% to 39%, confirming that SpA is the most frequent extra-intestinal manifestation in patients with IBD. In this paper, the expert panel presents some red flags to guide clinicians both rheumatologists and gastroenterologists - to make a correct diagnosis of IBD-associated SpA in clinical practice. IBD-associated SpA classification, clinical presentation and diagnostic work-up are also presented. From the therapeutic point of view, only separate recommendations/guidelines are currently available for the treatment of Crohn's disease, ulcerative colitis and for both axial and peripheral SpA. However, when IBD and SpA coexist, the therapeutic strategy should be modulated to take into account the variable manifestations of IBD in terms of intestinal and extra-intestinal features, and the clinical manifestations of SpA, with particular attention to peripheral enthesitis, dactylitis and anterior uveitis. To our knowledge, this is the first attempt to define therapeutic algorithms for the integrated management of different IBD-associated SpA clinical scenarios.
Spondyloarthritis; Inflammatory bowel disease; Integrated management; Crohn's disease; Ulcerative colitis; Therapeutic algorithm; evidence-based consensus; society classification criteria; Crohns-disease; ulcerative-colitis; extraintestinal manifestations; ankylosing-spondylitis; theumatic manifestations; axial spondyloarthritis; peripheral arthritis; induced osteoporosis
Settore MED/12 - Gastroenterologia
Article (author)
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S1568997214001049-main.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 904.55 kB
Formato Adobe PDF
904.55 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/254454
Citazioni
  • ???jsp.display-item.citation.pmc??? 18
  • Scopus 74
  • ???jsp.display-item.citation.isi??? 68
social impact